Holen Sie sich die Stockscreener-App
2.76
2.47%
-0.07
Handel nachbörslich:
2.81
0.05
+1.81%
Schlusskurs vom Vortag:
$2.83
Offen:
$2.8
24-Stunden-Volumen:
356.49K
Relative Volume:
0.26
Marktkapitalisierung:
$173.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-1.5506
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
-4.83%
1M Leistung:
+89.04%
6M Leistung:
+227.64%
1J Leistung:
+142.11%
1-Tages-Spanne:
$2.74
$2.99
1-Wochen-Bereich:
$2.3704
$2.99
52-Wochen-Spanne:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Vergleichen Sie PRLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
2.76 | 177.91M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Will Prelude Therapeutics Incorporated stock benefit from AI adoptionJuly 2025 Rallies & Free Real-Time Market Sentiment Alerts - ulpravda.ru
Quarterly Trades: Is Prelude Therapeutics Incorporated stock positioned well for digital economyStop Loss & Free Daily Entry Point Trade Alerts - ulpravda.ru
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MSN
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December - MarketBeat
Bullish Prelude Therapeutics Insiders Rewarded As Their Investment Rises To US$2.75m - Sahm
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1%What's Next? - MarketBeat
How Prelude Therapeutics Incorporated stock compares to industry benchmarksJuly 2025 Retail & Step-by-Step Trade Execution Guides - Улправда
What dividend safety score for Prelude Therapeutics Incorporated stock2025 Key Lessons & Risk Controlled Swing Alerts - Улправда
How Prelude Therapeutics Incorporated stock responds to policy changesEarnings Overview Summary & Scalable Portfolio Growth Methods - Улправда
Risk Analysis: What technical signals suggest for Prelude Therapeutics Incorporated stockForecast Cut & High Yield Stock Recommendations - Улправда
Is Prelude Therapeutics Incorporated stock a buy before product launches2025 Price Action Summary & Technical Pattern Based Signals - Улправда
Trend Report: Can Prelude Therapeutics Incorporated stock resist market sell offsJuly 2025 Setups & Free High Return Stock Watch Alerts - Улправда
Is Prelude Therapeutics Incorporated stock positioned well for digital economyPrice Action & Technical Confirmation Alerts - DonanımHaber
Is Prelude Therapeutics Incorporated stock overvalued by current metricsVolume Spike & Long-Term Investment Growth Plans - DonanımHaber
Will Prelude Therapeutics Incorporated stock reach all time highs in 2025Earnings Recap Report & Smart Swing Trading Techniques - DonanımHaber
Will Prelude Therapeutics Incorporated stock pay special dividends2025 Dividend Review & Daily Profit Maximizing Tips - DonanımHaber
Can Prelude Therapeutics Incorporated stock sustain revenue growthJuly 2025 News Drivers & Fast Gain Swing Trade Alerts - DonanımHaber
Why Prelude Therapeutics Incorporated stock attracts global investors2025 Dividend Review & Daily Profit Maximizing Tips - Bölüm Sonu Canavarı
What technical signals suggest for Prelude Therapeutics Incorporated stockJuly 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
Is Prelude Therapeutics Incorporated stock a buy for dividend growthJuly 2025 Closing Moves & Weekly Top Gainers Trade List - Улправда
Prelude Therapeutics Earnings Notes - Trefis
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Prelude Therapeutics divulges new JAK2 inhibitors - BioWorld MedTech
It makes sense and dollars to buy Prelude Therapeutics Inc (PRLD) stock - setenews.com
Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs - MSN
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Prelude Therapeutics (PRLD) Reveals Promising Preclinical Data a - GuruFocus
Prelude Therapeutics Unveils Promising Preclinical Data for JAK2V617F-selective JH2 Inhibitor and mCALR-targeted Degrader Antibody Conjugate at ASH 2025 - Quiver Quantitative
Prelude Therapeutics Presents Data at the 2025 ASH Annual - GlobeNewswire
Upcoming Events - FinancialContent
What insider trading reveals about Prelude Therapeutics Incorporated stockShort Setup & Daily Volume Surge Trade Alerts - Newser
Penny Stocks To Consider In December 2025 - simplywall.st
VIX Spike: How Prelude Therapeutics Incorporated stock compares to industry benchmarksJuly 2025 Decliners & Growth Focused Stock Pick Reports - moha.gov.vn
Growth Report: What dividend safety score for Prelude Therapeutics Incorporated stockJuly 2025 Big Picture & Daily Volume Surge Signals - moha.gov.vn
PRLD Investors Have Opportunity to Join Prelude - GlobeNewswire
This trade activity should not be overlooked: Prelude Therapeutics Inc (PRLD) - Setenews
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus - TradingView — Track All Markets
Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends - Markets Mojo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics IncorporatedPRLD - PR Newswire
Will Prelude Therapeutics Incorporated stock outperform Dow Jones indexJuly 2025 Sentiment & Smart Money Movement Alerts - newser.com
Is Prelude Therapeutics Incorporated stock supported by innovation pipeline2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation ... - Bakersfield.com
Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What to do if you’re stuck in Prelude Therapeutics IncorporatedPortfolio Update Summary & Smart Investment Allocation Insights - newser.com
User | poteaudailynews.comTargeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - FinancialContent
Is Prelude Therapeutics Incorporated stock ready for a breakoutJuly 2025 Sector Moves & Weekly Market Pulse Updates - newser.com
What sentiment indicators say about Prelude Therapeutics Incorporated stock2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 - MyChesCo
Order flow analysis tools used on Prelude Therapeutics IncorporatedJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Can Prelude Therapeutics Incorporated stock hit analyst price targets2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):